Lovastatin CAS: 75330-75-5
MF: C24H36O5
MW: 404.54
A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels).

Lovastatin (CAS 75330-75-5)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 130ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
5
0
4
0
3
1
2
0
1
0
Sinónimo: Mevacor;Monacolin K;mevinolin;6-α-Methylcompactin
Solicitud: A hypocholesterolemic HMGCR inhibitor (statin that lowers cholesterol levels)
Número de CAS: 75330-75-5
Pureza: ≥97%
Peso Molecular: 404.54
Fórmula Molecular: C24H36O5
* En el Certificado de Análisis específico de lote, puede encontrar información específica (como el contenido en agua).
Envíe una reseña para este producto y reciba 15 créditos Cruz

Lovastatin is a statin natural product isolated from numerous sources including the Pleurotus ostreatus oyster mushroom, demonstrating hypocholesterolemic and antiproliferative properties. Lovastatin inhibits HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), blocking the enzyme-catalyzed transformation of 3-hydroxy-3-methylglutaryl CoA into mevalonate. The biosynthesis of cholesterol requires mevalonate as a building block and elimination of mevalonate generation subsequently interrupts cholesterol synthesis, leading to a reduction of circulating low-density lipoproteins. Lovastatin demonstrates arrest of the cell cycle at the G1 phase in bladder carcinoma T24 cells expressing activated p21ras oncoprotein - the posttranslational isoprenylation of the p21ras with mevalonate is crucial for translocation and membrane adhesion of the protein, and blockade of this modification by Lovastatin-induced depletion of cellular mevalonate leads to suspension of cell progress. The signaling activity of epidermal growth factor (EGF) and insulin-like growth factor (IGF-I) are similarly affected by impairment of mevalonate-dependent protein prenylation. Induction of apoptosis by Lovastatin in malignant mesothelioma cells is also ascribed to the inhibition of mevalonate synthesis and posttranslational protein modifications. Lovastatin is a substrate of CYP and Mdr-1.


References

1. Alberts, A.W. 1988. Am. J. Cardiol. 62: 10J-15J. PMID: 3055919
2. Hancock, J.F., et al. 1989. Cell. 57: 1167-1177. PMID: 2661017
3. Mendola, C.E. and Backer, J.M. 1990. Cell Growth Differ. 1: 499-502. PMID: 2278880
4. Vincent, T.S., et al. 1991. Biochem. Biophys. Res. Commun. 180: 1284-1289. PMID: 1953779
5. Jakóbisiak, M., et al. 1991. Proc. Natl. Acad. Sci. U.S.A. 88: 3628-3632. PMID: 1673788
6. Rubins, J.B., et al. 1998. Am. J. Respir. Crit. Care Med. 157: 1616-1622. PMID: 9603146
7. Bobek, P., et al. 1998. Nutrition. 14: 282-286. PMID: 9583372
8. Kim, W.S., et al. 2001. Invest New Drugs. 19: 81-83. PMID: 11291836

Estado de Materia :
Solid
Forma Derivada :
Non-native source; synthetic
Solubilidad :
Soluble in DMSO (10 mg/ml), ethanol (10 mg/ml), methanol, chloroform, acetone, acetonitrile, DMF, and water (0.4 µg/ml).
ALMACENAMIENTO :
Store at -20° C
Punto de Fusión :
175.4° C
Punto de ebullición :
~559.2° C at 760 mmHg (Predicted)
Densidad :
~1.1 g/cm3 (Predicted)
Indice de Refracción :
n20D 1.53
Actividad Óptica :
α20/D 320°±10°, c = 0.5 in CH3CN
IC50 :
HMG-CoA reductase: IC50 = 0.01 µM (rat); Inhibition of the incorporation of sodium [14C]acetate into cholesterol: IC50 = 0.05 µM (HEP G2 cells); inhibition of recombinant ICAM-1 binding to purified immobilized LFA-1: IC50 = 3.78 µM; CYP51: IC50 = 200 µM (human)
Datos Ki :
HMG-CoA reductase: Ki= 0.6 nM
Para Uso Exclusivo en Investigación. No está diseñado para uso en diagnosis o terapia.
WGK Alemania :
3
RTECS :
EK7907000
PubChem CID :
53232
Indice de Merck :
14: 5586
Número MDL :
MFCD00072164

Descargar SDS (MSDS)

CERTIFICADO DE ANÁLISIS

Necesita Adobe Acrobat Reader para ver de forma fiable,
imprimir y comentar el documento de PDF

Lovastatin  Menciones del Producto

Ver como otros han utilizado Lovastatin. Haga click en la entrada de PubMed .

Citaciones 1 a 7 de un total de 7

PMID: # 27159577  Shimada, K. et al. 2016. Nature chemical biology. 12: 497-503.

PMID: # 26243146  Meunier, S. et al. 2015. Nature communications. 6: 7889.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 10196184  Reimer, CL. et al. 1999. J. Biol. Chem. 274: 11022-11029.

PMID: # 9653194  De Petrocellis, L. et al. 1998. Proc. Natl. Acad. Sci. USA. 95: 8375-8380.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

PMID: # 9341167  Vogt, A. et al. 1997. J. Biol. Chem. 272: 27224-27229.

Citaciones 1 a 7 de un total de 7
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 128ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 11ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

Santa Cruz Biotechnology, Inc. es un líder mundial en el desarrollo de productos para el mercado de la investigación biomédica. Llámenos gratis al 00 800 4573 8000.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved."Santa Cruz Biotechnology", y el logo de Santa Cruz Biotechnology, Inc., "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", el logo de San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", y "EZ Touch" son marcas registradas de Santa Cruz Biotechnology, Inc. Todas las marcas registradas son propiedad de su respectivo dueño.